Alpine Immune Sciences Inc (DELISTED) (ALPN:DL)
64.97
0.00 (0.00%)
USD |
NASDAQ |
May 20, 16:00
Alpine Immune Sciences Shareholders Equity (Quarterly): 332.70M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 332.70M |
December 31, 2023 | 327.94M |
September 30, 2023 | 161.63M |
June 30, 2023 | 169.39M |
March 31, 2023 | 169.54M |
December 31, 2022 | 179.42M |
September 30, 2022 | 182.01M |
June 30, 2022 | 99.54M |
March 31, 2022 | 115.43M |
December 31, 2021 | 120.90M |
September 30, 2021 | 122.82M |
June 30, 2021 | 43.83M |
March 31, 2021 | 53.29M |
December 31, 2020 | 62.16M |
September 30, 2020 | 67.47M |
June 30, 2020 | 16.23M |
March 31, 2020 | 24.86M |
December 31, 2019 | 29.47M |
September 30, 2019 | 34.83M |
Date | Value |
---|---|
June 30, 2019 | 45.42M |
March 31, 2019 | 56.58M |
December 31, 2018 | 44.59M |
September 30, 2018 | 54.98M |
June 30, 2018 | 66.55M |
March 31, 2018 | 73.88M |
December 31, 2017 | 78.92M |
September 30, 2017 | 82.97M |
June 30, 2017 | 46.07M |
March 31, 2017 | 49.22M |
December 31, 2016 | 55.44M |
September 30, 2016 | 62.10M |
June 30, 2016 | 68.69M |
March 31, 2016 | 76.36M |
December 31, 2015 | 83.49M |
September 30, 2015 | 89.38M |
June 30, 2015 | 95.12M |
March 31, 2015 | -19.92M |
December 31, 2014 | -15.75M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
16.23M
Minimum
Jun 2020
332.70M
Maximum
Mar 2024
121.76M
Average
115.43M
Median
Mar 2022
Shareholders Equity (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | 14.77B |
Eliem Therapeutics Inc | 222.28M |
Regeneron Pharmaceuticals Inc | 28.21B |
Vera Therapeutics Inc | 327.87M |
Eyenovia Inc | -2.370M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 373.65M |
Total Liabilities (Quarterly) | 40.94M |
Current Ratio | 9.562 |
Net Debt Paydown Yield | 0.03% |